The new drug application for mirdametinib included data from the phase IIb ReNeu trial, which evaluated patients with NF1-associated plexiform neurofibromas, which cause significant morbidity.
FDA grants Priority Review to mirdametinib for neurofibromatosis type 1-associated plexiform neurofibromas
Leave a comment
